Clinical Trial Update: Weight-Adjusted Dosing of 3-OHB in Patients With Chronic Heart Failure [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating weight-adjusted dosing of 3-hydroxybutyrate (3-OHB) in patients with chronic heart failure.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• 3-hydroxybutyrate (beta-hydroxybutyrate)

Snippet

Sponsor: University of Aarhus | Conditions: Heart Failure, Ketosis | Phase 2 | Status: UNKNOWN